
## David Z D'argenio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8932712/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Physiologically Based Modeling to Predict Monoclonal Antibody Pharmacokinetics in Humans from in vitro Physiochemical Properties. MAbs, 2022, 14, 2056944.	5.2	13
2	Biokinetic modeling of nanoparticle interactions with lung alveolar epithelial cells: uptake, intracellular processing, and egress. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2021, 320, R36-R43.	1.8	4
3	An Analysis of Glucose Effectiveness in Subjects With or Without Type 2 Diabetes via Hierarchical Modeling. Frontiers in Endocrinology, 2021, 12, 641713.	3.5	2
4	Characteristics of Passive Solute Transport across Primary Rat Alveolar Epithelial Cell Monolayers. Membranes, 2021, 11, 331.	3.0	4
5	A wholeâ€body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 671-683.	2.5	0
6	Open‣ource Maximum a Posteriori â€Bayesian Dosing AdDS to Current Therapeutic Drug Monitoring: Adapting to the Era of Individualized Therapy. Pharmacotherapy, 2021, 41, 953-963.	2.6	2
7	Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony–Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation. AAPS Journal, 2020, 22, 143.	4.4	5
8	The Efficiency, Efficacy, and Retention of Task Practice in Chronic Stroke. Neurorehabilitation and Neural Repair, 2020, 34, 881-890.	2.9	17
9	Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 385-409.	1.8	18
10	A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 163-182.	1.8	8
11	Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function. Therapeutic Drug Monitoring, 2020, 42, 856-865.	2.0	3
12	Analytical solution of linear multi-compartment models with non-zero initial condition and its implementation with R. Translational and Clinical Pharmacology, 2019, 27, 43.	0.9	3
13	Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	13
14	RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology. DNA Repair, 2017, 52, 24-30.	2.8	3
15	Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice. Peptides, 2017, 88, 74-79.	2.4	28
16	Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	36
17	Feedback control indirect response models. Journal of Pharmacokinetics and Pharmacodynamics, 2016, 43, 343-358.	1.8	9
18	Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw553.	3.0	6

DAVID Z D'ARGENIO

#	Article	IF	CITATIONS
19	Feedback Control Indirect Response Models. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 229-253.	0.6	1
20	Reply to Scagnolari et al Journal of Infectious Diseases, 2016, 215, jiw580.	4.0	0
21	Human insulin dynamics in women: a physiologically based model. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 310, R268-R274.	1.8	5
22	Modeling Ribavirinâ€Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 65-73.	2.5	14
23	Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 2179-2188.	3.2	28
24	FLT3 and CDK4/6 inhibitors: Signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 675-691.	1.8	6
25	Glucagon clearance is regulated by nutritional state: evidence from experimental studies in mice. Diabetologia, 2014, 57, 801-808.	6.3	7
26	Integrated Population Pharmacokinetic/Viral Dynamic Modelling of Lopinavir/Ritonavir in HIV-1 Treatment-NaĀ <sup>-</sup> ve Patients. Clinical Pharmacokinetics, 2014, 53, 361-371.	3.5	13
27	The International Society of Pharmacometrics. Journal of Pharmacokinetics and Pharmacodynamics, 2013, 40, 3-4.	1.8	2
28	Population-Based Efficacy Modeling of Omalizumab in Patients with Severe Allergic Asthma Inadequately Controlled with Standard Therapy. AAPS Journal, 2013, 15, 559-570.	4.4	9
29	Analysis of Intravenous Glucose Tolerance Test Data Using Parametric and Nonparametric Modeling: Application to a Population at Risk for Diabetes. Journal of Diabetes Science and Technology, 2013, 7, 952-962.	2.2	3
30	Pharmacokinetics of Doxycycline in Adults with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 70-74.	3.2	47
31	Isoniazid Pharmacokinetics, Pharmacodynamics, and Dosing in South African Infants. Therapeutic Drug Monitoring, 2012, 34, 446-451.	2.0	31
32	Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 577-590.	1.8	9
33	The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid. Journal of Clinical Pharmacology, 2012, 52, 511-519.	2.0	31
34	A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D3 is revealed using a novel LC–MS/MS assay. Steroids, 2012, 77, 477-483.	1.8	14
35	Affiliation between the American Society of Pharmacometrics and the Journal of Pharmacokinetics and Pharmacodynamics. Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39, 3-3.	1.8	1
36	Editorial: Special Issue on Multiscale Modeling and Analysis in Computational Biology and Medicine—Part-1. IEEE Transactions on Biomedical Engineering, 2011, 58, 2936-2942.	4.2	6

DAVID Z D'ARGENIO

#	Article	IF	CITATIONS
37	Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemotherapy and Pharmacology, 2011, 67, 421-430.	2.3	9
38	Editorial: TBME Letters Special Issue on Multiscale Modeling and Analysis in Computational Biology and Medicine—Part-2. IEEE Transactions on Biomedical Engineering, 2011, 58, 3434-3439.	4.2	3
39	Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1126-R1133.	1.8	11
40	Defining the Future of Pharmacometrics: The American Society of Pharmacometrics. Journal of Clinical Pharmacology, 2010, 50, 158S.	2.0	3
41	Bridging Pharmacology and Pathophysiology via Systems Modeling. Journal of Clinical Pharmacology, 2010, 50, 56S-57S.	2.0	1
42	ACoP: The Tools, Carpenters, and Architects Building the Discipline of Pharmacometrics. Journal of Clinical Pharmacology, 2010, 50, 7S-8S.	2.0	1
43	Vitreous VEGF Clearance Is Increased after Vitrectomy. , 2010, 51, 2135.		104
44	Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. Bioinformatics, 2010, 26, 807-813.	4.1	28
45	The Emerging Scientific Discipline of Pharmacometrics. Journal of Clinical Pharmacology, 2010, 50, 6S.	2.0	25
46	Abstract 4549: Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. , 2010, , .		0
47	Population pharmacokinetic/pharmacodynamic mixture models via maximum a posteriori estimation. Computational Statistics and Data Analysis, 2009, 53, 3907-3915.	1.2	4
48	Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Cancer Chemotherapy and Pharmacology, 2008, 62, 457-64.	2.3	20
49	Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatric Blood and Cancer, 2008, 50, 757-760.	1.5	4
50	A Note on Population Analysis of Dissolutionâ€Absorption Models Using the Inverse Gaussian Function. Journal of Clinical Pharmacology, 2008, 48, 719-725.	2.0	15
51	Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm. Computational Statistics and Data Analysis, 2007, 51, 6614-6623.	1.2	18
52	Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemotherapy and Pharmacology, 2006, 58, 13-23.	2.3	118
53	A Mass Balance and Disposition Study of the DNA Methyltransferase Inhibitor Zebularine (NSC 309132) and Three of Its Metabolites in Mice. Clinical Cancer Research, 2006, 12, 5826-5833.	7.0	9
54	Model for Intracellular Lamivudine Metabolism in Peripheral Blood Mononuclear Cells Ex Vivo and in Human Immunodeficiency Virus Type 1-Infected Adolescents. Antimicrobial Agents and Chemotherapy, 2006, 50, 2686-2694.	3.2	17

DAVID Z D'ARGENIO

#	Article	IF	CITATIONS
55	Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice. Journal of Pharmacokinetics and Pharmacodynamics, 2003, 30, 185-219.	1.8	52
56	Parameter estimation of the sparse data systems using a smoothed-likelihood estimator. , 1992, , .		0
57	A Neural Network for Nonlinear Bayesian Estimation in Drug Therapy. Neural Computation, 1990, 2, 216-225.	2.2	15
58	Discrete approximation of multivariate densities with application to Bayesian estimation. Computational Statistics and Data Analysis, 1984, 2, 27-36.	1.2	17